USPTO serial 90106080
YODA
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- INGRAM, KYLE G
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with YODA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Hui Zhang
Hui Zhang RABIN & BERDO, P.C.2650 PARK TOWER DRIVE, SUITE 800VIENNA, VA 22180UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of central nervous system disorders or diseases, namely, neurological illnesses, psychiatric illnesses, and neurodegenerative diseases; pharmaceutical preparations for the treatment of psychiatric, emotional and behavioral disorders, namely, depression, bi-polar disorder, anxiety, panic disorder, schizophrenia, schizoaffective disorder, positive syndrome, negative syndrome, mood and cognitive related symptoms of psychiatric illnesses, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD); pharmaceutical preparations for the treatment of brain injuries, namely, traumatic brain injury (TBI), brain ischemia, post-stroke recovery, post-hemorrhage recovery, reversible cerebral vasoconstriction syndrome, spinal cord injury, convulsion, epileptic seizures; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD); pharmaceutical preparations for the treatment of loss of memory, cognition, or loss of neuronal functions associated with neurodegenerative diseases or aging; pharmaceutical preparations for the treatment of neurological diseases, namely, ataxia, sporadic or hereditary ataxias, cerebellar ataxia, parkinsonism ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), muscular dystrophy; pharmaceutical preparations for the treatment of neurodevelopmental disorders, namely, Tourette syndrome (TS), autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), developmental language disorder (DLD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of pain, namely, neuropathic pain; Pharmaceutical preparations for the treatment of inflammatory disorder or diseases, namely, inflammasome-related diseases, immunological diseases; pharmaceutical preparations for the treatment of auto-inflammatory diseases or auto-immune diseases, namely, multiple sclerosis (MS), systemic sclerosis (SSc), rheumatoid arthritis (RA), lupus, gout, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, chronic inflammation, auto-inflammatory fever syndromes, cryopyrin-associated periodic syndromes (CAPS); pharmaceutical preparations for the treatment of liver-related inflammatory diseases, namely, chronic liver disease, non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, viral hepatitis; pharmaceutical preparations for the treatment of kidney-related inflammatory diseases, namely, chronic kidney disease (CKD), hypertensive nephropathy, lupus nephritis, Type I diabetes, Type II diabetes, hemodialysis related inflammation; pharmaceutical preparations for the treatment of cardiovascular-related inflammatory diseases, namely, chronic heart disease (CHD), peripheral artery disease (PAD), hypertension, atherosclerosis, acute heart failure, systemic lupus erythematosus (SLE); pharmaceutical preparations for the treatment of neuroinflammation-related diseases, namely, Parkinson's disease (PD), Alzheimer's disease (AD), dementia, mild cognitive impairment (MCI), Huntington's disease (HD), traumatic brain injury (TBI), brain ischemia, ataxia, multiple system atrophy (MSA), Friedreich's ataxia, spinocerebellar ataxia, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), multiple sclerosis (MS), muscular dystrophy, Tourette syndrome (TS), autism spectrum disorder (ASD), Fragile-X syndrome (FXS), Rett syndrome, cerebral palsy; pharmaceutical preparations for the treatment of age-related inflammatory degenerative diseases, namely, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), parkinsonism-dementia complex of Guam, atherosclerosis, osteoarthritis, neuronal cell death; Pharmaceutical drugs, namely, anti-inflammatory agents, antioxidants, antidepressants, antipsychotics, anti-Parkinson agents, central nervous system agents, stimulants, inhibitors, modulators, benzodiazepines, serotoninergic agents, dopaminergic agents, glutaminergic agents, analgesics, neuromuscular agents, and psychotherapeutic agents | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 24, 2021 | MAB5 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | — |
| Aug 23, 2021 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Aug 16, 2021 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Jul 20, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 20, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 30, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 14, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 28, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 5, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 12, 2020 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 11, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 14, 2020 | NWAP | NEW APPLICATION ENTERED | — |